GENERAL NOTICE

NOTICE 503 OF 2008

DEPARTMENT OF HEALTH

ERRATUM - Notice 434 of 2008

General Notice 434 of 2008, published in Government Gazette No. 30957 vol. 514 of 11 April 2008 had been changed but the old version was submitted for publication in error.

GENERAL NOTICE
ALGEMENE KENNISGEWING

NOTICE 434 OF 2008

MEDICINES CONTROL COUNCIL

CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)

1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council.
2. The manufacture of this medicine is subject to regular investigation and inspections by the inspectors appointed in terms of Section 26 of the Act, to assess compliance with current Good Manufacturing Practices.
3. The information in the package insert shall be updated on a regular basis to conform to the package insert recently approved by Council.
4. The applicant must comply with all the legal requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).
5. The registration of this medicine shall be subject to review at intervals as determined by Council regarding its quality, safety and efficacy, and the registration of this medicine may be varied subject to issues Council may deem fit.
6. The first two production batches must be fully validated in terms of the detailed process validation protocol submitted at the time of application for registration, and the validation report must be submitted within a month after completion of the validation.
7. The product may be advertised to the professions only.
8. A post-registration inspection must be conducted in the first production batch of the locally manufactured product.
9. A post-registration inspection must be conducted on the first production batch manufactured by each local manufacturer.
10. A post-registration inspection must be conducted on the first production batch of the imported product.
11. Marketing of the product may only commence following a satisfactory post-registration inspection report.
12. One sample of every batch, together with four copies of the protocol for testing of the bulk lot and filling lot, and six copies of the certificate of release issued by a competent authority in the country in which the product was manufactured, must be submitted to the Council for lot release purposes.
13. The expiry date allocated shall be modified by adding a statement that the virus strains are currently recommended for South African usage in the specific year.
14. The strains of the master seed viruses must be approved by the Department of Health for each year.